Manulife (Manufacturers Life Insurance)
BCLI

Manulife (Manufacturers Life Insurance)’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,211
Closed -$82K – 3080
2020
Q4 		$82K Buy
1,211
+122
+11% +$16.6K ﹤0.01% 2963
2020
Q3 		$276K Hold
1,089
– – ﹤0.01% 2348
2020
Q2 		$181K Buy
+1,089
New +$117K ﹤0.01% 2548

Other funds holding BCLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s BCLI Position: Q1 2021 in Review

Manulife (Manufacturers Life Insurance) sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2021, closing a stake of 1,211 shares — an estimated $82K sold.

Manulife (Manufacturers Life Insurance) first reported a position in BCLI in Q2 2020 and held it in 3 quarters. The position peaked at $276K in Q3 2020. 75 funds tracked by Wall St. Rank hold BCLI as of Q1 2021.

  • Manulife (Manufacturers Life Insurance) reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2021 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 1,211 BRAINSTORM CELL THERAPUTC shares in Q1 2021, an estimated $82K.
  • Manulife (Manufacturers Life Insurance) first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2020 and held it in 3 quarters.
  • Manulife (Manufacturers Life Insurance)'s BRAINSTORM CELL THERAPUTC position peaked at $276K in Q3 2020.
  • 75 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2021.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2021, filed 3 May 2021.